
Antimicrobial resistance (AMR) isn't going to be solved by new antibiotics alone—it also requires identifying resistant infections quickly enough to guide treatment and prevent transmission. In this episode of Behind the Breakthroughs, Anne Beaubrun, PhD, of Cepheid and Amish Acharya, PhD, of the Fleming Initiative, discuss how rapid molecular diagnostics, including the TRACE-CPE study, could bring precision medicine to infectious disease by enabling earlier detection of carbapenemase-producing Enterobacterales (CPE)—dangerous, last-resort antibiotic-resistant bacteria that are spreading rapidly in hospitals. They also explore the scientific, clinical, and policy challenges of making rapid diagnostics a routine part of healthcare worldwide.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by Erick Ziegler
Brought to you by Inside Precision Medicine (SAGE Publishing)
Medicine is full of breakthroughs. Most don't become medicine. Behind the Breakthroughs explores scientific ideas that could change how we diagnose and treat disease—and what it will take for them to work. Host Jonathan D. Grinstein, PhD, a scientist-turned-journalist, speaks with the researchers, physicians, and entrepreneurs building the next generation of genetic medicines, diagnostics, AI, precision therapeutics, and biotechnology.
Hosted on Acast. See acast.com/privacy for more information.
More episodes from "Behind the Breakthroughs"



Don't miss an episode of “Behind the Breakthroughs” and subscribe to it in the GetPodcast app.








